DJIA 16,262.56 89.32 0.55%
NASDAQ 4,034.16 0.00 0.00%
S&P 500 1,842.98 12.37 0.68%
market minute promo

13.24 0.21 (1.61%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

NBIX $13.24 1.61%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.08
Previous Close $13.03
Daily Range $12.17 - $13.35
52-Week Range $8.57 - $20.29
Market Cap $997.6M
P/E Ratio -18.96
Dividend (Yield) $0.00 (0.0%)
Volume 814,921
Average Daily Volume 1,146,360
Current FY EPS -$0.86





Neurocrine Biosciences, Inc. (NBIX) Description

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis. Website:

News & Commentary

Neurocrine Biosciences Is Now Oversold (NBIX)

Neurocrine Biosciences (NBIX) Shares Cross Below 200 DMA

Commit To Purchase Neurocrine Biosciences At $11, Earn 23.9% Annualized Using Options

Heavy Trading On Neurocrine Biosciences (NBIX) Before Market Open

US Stock Futures Tumble Ahead Of Durable-Goods Orders, Jobless Claims Data

Fundamentals Continue To Look Strong At Neurocrine Bio

Neurocrine Biosciences' CEO Discusses Q4 2013 Results - Earnings Call Transcript

Can You Still Ride This Month's 3 Biggest Winners To Greater Gains?

Biotech dominates in January as Intercept, Cell Therapeutics, and Neurocrine all surge after good drug-trial news.

Piper Jaffray’s Seven Biotech Stocks to Buy With Huge Potential Upside

3 Stocks to Get on Your Watchlist

A big-box retail giant, an up-and-coming developer of a tardive dyskinesia treatment, and a short-sale candidate.

See More NBIX News...

NBIX's Top Competitors

NBIX $13.24 (1.61%)
Current stock: NBIX
AMGN $115.00 (1.48%)
Current stock: AMGN
GILD $68.17 (2.07%)
Current stock: GILD
BIIB $285.49 (2.14%)
Current stock: BIIB